O’Melveny Represents Rainmed Medical in its Hong Kong IPO

July 08, 2022



HONG KONG—JULY 8, 2022—O’Melveny recently represented Rainmed Medical Limited (2297.HK) in its IPO and listing on the Hong Kong Stock Exchange. The transaction marks O’Melveny’s 11th successful Chapter 18A Hong Kong IPO for biotech companies.

Founded in 2014, Rainmed Medical Limited is a China-based medical device company, with current focus on the design, development and commercialization of coronary angiography-derived fractional flow reserve system and coronary angiography-derived index of microvascular resistance system. 

Huatai Financial Holdings (Hong Kong) Limited acted as the Sole Sponsor and Sole global coordinator for this IPO.

The O’Melveny team was led by partners Ke Geng and Ke Zhu, with assistance from counsel Yazhe Liu and Xueyin Zhong, associates Stella Yang and Jingwei Huang, legal consultants Minhui Chen, Yirong Du, Elle Mei and Iris Su, paralegal Aileen Xu and trainee solicitor Jeffrey Hang. Partners Rob Plesnarski and Kurt Berney, counsel Billy Abbott and associate Dawn Lim provided tax and U.S. legal opinion related advice.

About O’Melveny

It’s more than what you do: it’s how you do it. Across sectors and borders, in board rooms and courtrooms, we measure our success by yours. And in our interactions, we commit to making your O’Melveny experience as satisfying as the outcomes we help you achieve. Our greatest accomplishment is ensuring that you never have to choose between premier lawyering and exceptional service. So, tell us. What do you want to achieve? Visit us at www.omm.com, hear what our lawyers, staff, and clients have to say in Our DNA video series, or learn more in our firm at-a-glanceannual report, and on LinkedIn,  TwitterFacebookInstagram, and YouTube. Visit The Boardroom for our insights on pressing issues facing global corporations.


Brandon Jacobsen
O’Melveny & Myers LLP
+1 213 430 8024

Chris Schob
O’Melveny & Myers LLP
+86 21 2307 7000